Healthy Tips

If you take medicine to lower uric acid, you may have heard questions about febuxostat and heart safety. This can sound frightening, especially if you already have heart disease.

The key is not to panic and not to stop gout medicine on your own. The safer approach is to understand what the CARES trial found and discuss your personal risk with your clinician.

What CARES studied

The CARES trial compared febuxostat with allopurinol in people who had gout and established cardiovascular disease. That means the study focused on a higher-risk group, not every person with gout.

The main combined cardiovascular outcome was similar between the two medicines. However, the trial reported higher cardiovascular death and higher death from any cause in the febuxostat group than in the allopurinol group.

This finding led to extra caution around febuxostat use, especially for patients with known cardiovascular disease.

What this means in real life

Febuxostat can lower uric acid and may be used when allopurinol is not tolerated or is not appropriate. But for someone with a history of heart attack, stroke, heart failure, angina, or other major cardiovascular disease, the choice deserves careful discussion.

Allopurinol is often tried first, when suitable. Febuxostat may still be the right choice for some patients, but the reason should be clear and documented.

Do not stop suddenly without advice

Stopping urate-lowering therapy can allow uric acid to rise again. Over time, that can increase the chance of more flares and crystal buildup. If you are worried about febuxostat, call your clinician and ask for a medication review.

For related GoutBye reading, see patient education, lifestyle strategies, flare management, and exercise.

Questions to ask your clinician

• Why was febuxostat or allopurinol chosen for me?
• Do I have cardiovascular disease that changes the decision?
• What uric acid goal should I reach?
• Could I use allopurinol safely, or have I already had a reason not to?
• What symptoms should make me seek urgent care?

Bottom line

The CARES trial did not say that every person must avoid febuxostat. It did show a heart safety signal in people with gout and established cardiovascular disease. If you are taking febuxostat, the best next step is a calm review with your clinician, not a sudden stop.

Resources: White WB and colleagues. “Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.” New England Journal of Medicine. 2018;378:1200-1210. doi: 10.1056/NEJMoa1710895.

Related gout reading

• Allopurinol and heart health
• Gout and heart risk
• Starting uric acid treatment during a flare
• What changed in gout care

Resources: CARES trial research on febuxostat, allopurinol, cardiovascular safety, and gout treatment decisions.